0001493152-21-004498 | 6-K | XBRL Viewer

Document Entity Information	9 Months Ended
Document Entity Information	Sep. 30, 2020
Cover [Abstract]
Entity Registrant Name	Brainsway Ltd.
Entity Central Index Key	0001505065
Document Type	6-K
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Interim Consolidated Statements of Financial Position - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 30, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 15,792	$ 21,674
Short-term deposits	221	221
Trade receivables, net	6,531	5,507
Other accounts receivable	1,531	1,427
Total current assets	24,075	28,829
NON-CURRENT ASSETS:
Long-term deposit	163	168
Leased systems	5,139	5,491
System components and other property and equipment	5,004	4,248
Total non-current assets	10,306	9,907
Total assets	34,381	38,736
CURRENT LIABILITIES:
Trade payables	911	1,320
Other accounts payable	3,817	3,379
Deferred revenues	1,184	1,305
Liability in respect of research and development grants	1,060	714
Total current liabilities	6,972	6,718
NON-CURRENT LIABILITIES:
Deferred revenues and other liabilities	2,178	2,431
Liability in respect of research and development grants	5,319	5,367
Total non-current liabilities	7,497	7,798
EQUITY:
Share capital	233	233
Share premium	95,111	93,649
Share-based payment	3,644	4,435
Adjustments arising from translating financial statements from functional currency to presentation currency	(2,188)	(2,188)
Accumulated deficit	(76,888)	(71,909)
Total equity	19,912	24,220
Total equity and liabilities	$ 34,381	$ 38,736

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Profit or loss [abstract]
Revenues	$ 14,991	$ 16,809
Cost of revenues	3,492	3,687
Gross profit	11,499	13,122
Research and development expenses, net	4,247	6,067
Selling and marketing expenses	8,284	9,665
General and administrative expenses	3,390	3,875
Total operating expenses	15,921	19,607
Operating loss	4,422	6,485
Finance expense, net	80	1,252
Loss before income taxes	4,502	7,737
Income taxes	477	275
Net loss and total comprehensive loss	$ 4,979	$ 8,012
Weighted number of shares	22,248,259	22,236,368
Basic and diluted net loss per share	$ (0.22)	$ (0.40)

Condensed Interim Consolidated Statements of Changes in Equity (Unaudited) - USD ($)
$ in Thousands

Share Capital [Member]

Share Premium [Member]

Reserve for Share-Based Payment Transactions [Member]

Adjustments Arising from Translating Financial Statements From Functional Currency to Presentation Currency [Member]

Accumulated Deficit [Member]

Total

Beginning Balance at Dec. 31, 2018

$ 171

$ 67,193

$ 3,357

$ (2,188)

$ (61,581)

$ 6,952

IfrsStatementLineItems [Line Items]

Net loss and total comprehensive loss

(8,012)

Expiration of share options

184

(184)

Cost of share-based payment

981

Issuance of shares, net

^[1]

26,302

26,333

Ending Balance at Sep. 30, 2019

202

93,679

4,154

(2,188)

(69,593)

24,220

Beginning Balance at Dec. 31, 2019

233

93,649

4,435

(2,188)

(71,909)

24,220

IfrsStatementLineItems [Line Items]

Net loss and total comprehensive loss

(4,979)

Exercise of share options

467

(467)

Expiration of share options

996

(996)

Cost of share-based payment

672

Ending Balance at Sep. 30, 2020

$ 233

$ 95,111

$ 3,644

$ (2,188)

$ (76,888)

$ 19,912

[1]	Net of issuance expenses of $ 2,290.

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2020-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2020-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2020-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2020-01-01

+ Details

Condensed Interim Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Statement of changes in equity [abstract]
Issuance expenses	$ 2,290	$ 2,290

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Total comprehensive loss	$ (4,979)	$ (8,012)
Adjustments to the profit or loss items:
Depreciation, amortization and impairment	1,271	1,401
Depreciation of leased systems	877	735
Finance expenses, net	80	1,252
Cost of share-based payment	671	981
Income taxes	477	275
Total adjustments to reconcile profit (loss)	3,376	4,644
Changes in asset and liability items:
Increase in trade receivables	(996)	(2,165)
Decrease (increase) in other accounts receivable	(94)	13
Increase (decrease) in trade payables	(422)	426
Increase (decrease) in other accounts payable	320	(257)
Increase (decrease) in deferred revenues and other liabilities	(27)	19
Total changes in asset and liability	(1,219)	(1,964)
Cash paid and received during the period for:
Interest paid	(59)	(267)
Interest received	54	127
Income taxes paid	(249)	(542)
Total cash paid and received during the year	(254)	(682)
Net cash used in operating activities	(3,076)	(6,014)
Cash flows from investing activities:
Purchase of property and equipment and system components	(2,555)	(2,973)
Investment in short-term deposits, net		(84)
Withdrawal of (Investment in) long-term deposits, net	5	1,007
Net cash used in investing activities	(2,550)	(2,050)
Cash flows from financing activities:
Repayment of loan from bank, net		(3,000)
Receipt of government grants	42	141
Repayment of liability in respect of research and development grants		(275)
Repayment of lease liability	(322)	(311)
Proceeds from issuance of shares, net		26,333
Net cash provided by (used in) financing activities	(280)	22,888
Exchange rate differences on cash and cash equivalents	24	(51)
Increase (decrease) in cash and cash equivalents	(5,882)	14,773
Cash and cash equivalents at the beginning of the period	21,674	8,968
Cash and cash equivalents at the end of the period	15,792	21,674
(a) Significant non-cash transactions:
Purchase of property and equipment on credit		$ 189

General

9 Months Ended

Sep. 30, 2020

General

General

NOTE 1:—GENERAL

a.	A general description of the Company and its activity:

Brainsway Ltd. (“the Company”), was incorporated on November 7, 2006, is a commercial stage medical device company focused on the development and sale of non-invasive Deep Transcranial Magnetic Stimulation (“Deep TMS”) technology for the treatment of neurological and addiction disorders. The Deep TMS system (“system”) uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain.

In January 2013, the first commercial Deep TMS system received clearance by the United States Food and Drug Administration (“FDA”) for the treatment of major depressive disorder (“MDD”) in adults who failed to achieve satisfactory improvement from anti-depressant medication. In August 2018, the Company received clearance of marketing authorization by the FDA for the adjunct therapy for the treatment of obsessive-compulsive disorder (OCD) in adults.

In August 24, 2020 Brainsway Ltd. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s deep transcranial magnetic stimulation (“Deep TMS”) system for its use as an aid in short-term smoking cessation in adults.

The Company and its wholly owned subsidiaries, Brainsway, Inc., Moach R&D Services Ltd. (“Moach”), and Brainsway USA Inc (“USA Inc”), collectively, the “Group,” derive revenues from the sale and lease of its systems.

In an effort to contain and mitigate the spread of COVID-19 global pandemic, many countries around the world, including the U.S. and Israel, have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and closed non-essential businesses and offices. As many local jurisdictions continue to have such restrictions in place, the company’s ability to continue to operate its business may also be limited.

To date, the financial impact on the Company’s business has been moderate, and the Company has put in place a comprehensive alternative commercial strategy to support growth initiatives while adhering to government and health regulatory guidelines. Additionally, to date, there have been no significant disruptions to the supply chain, and the Company currently has sufficient supply of components to assemble the Company’s Deep TMS systems and meet commercial demand. However, the Company has experienced decreased commercial activities which have affected the revenue from leases of the Company’s Deep TMS systems due to slower initiation of certain promotional activities associated with a significant decrease in in-clinic patient visits, tests and treatments and the impact on our sales force’s ability to engage with healthcare providers in an in-person setting, cancellation of events such as industry conferences and limited local and international travel. The ability to successfully commercialize the Deep TMS system for smoking addiction depends on in-clinic patient visits and the availability of diagnostics, both of which has have been negatively affected by the pandemic. In addition, the COVID-19 pandemic has adversely affected and may continue to adversely affect the Company’s clinical and pre-clinical trials, including the ability to initiate and complete clinical and pre-clinical trials within the anticipated timelines, and delays or difficulties in enrolling patients in clinical trials and recruiting clinical site investigators and clinical site staff.

c.	These financial statements have been prepared in a condensed format as of September 30, 2020 and for the nine period then ended (“Interim Consolidated Financial Statements”). These financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2019 and for the year then ended and accompanying notes (“Annual Consolidated Financial Statements”).

d.	The Group had negative cash flows from operating activities of approximately $3,076 and $6,014 for the nine months ended September 30, 2020 and for the nine months ended September 30, 2019, respectively. Furthermore, the Company had an operating loss of $4,422 and $6,485 for the nine months ended September 30, 2020 and for the nine months ended September 30, 2019, respectively. The Company’s management and board of directors believe that the Company has the current funding to finance its business activity according to its plans in the foreseeable future.

e.	The interim financial statements of the Company as of September 30, 2020 and for the nine-month periods ended September 30, 2020 and 2019 were authorized for issuance in accordance with a resolution of the board of directors on February 22, 2021.

Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Disclosure of initial application of standards or interpretations [abstract]

Significant Accounting Policies

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

a.	Basis of preparation of the interim consolidated financial statements:

The interim consolidated financial statements have been prepared in accordance with IAS 34, “Interim Financial Reporting.”

The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the Annual Consolidated Financial Statements.

b.	In the process of applying the significant accounting policies in the financial statements, the Group has made the following judgments, estimates and assumptions, which have the most significant effect on the amounts recognized in the financial statements:

(i)	Judgments:

Classification of leases:

Evaluation of whether to classify a lease as a finance lease or an operating lease in accordance with the criteria stipulated in IFRS 16 requires significant judgment.

(ii)	Estimates and assumptions:

The preparation of the financial statements requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.

The key assumptions made in the financial statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

●

Grants from the Israel Innovation Authority (“IIA”):

Government grants received from the IIA are recognized as a liability if future economic benefits are expected from the research and development activity that will result in royalty-bearing sales. There is uncertainty regarding the estimated future cash flows and discount rate used to measure the amount of the liability.

●

Provision for allowance for doubtful accounts on trade receivables:

The Group uses a provision matrix to calculate the allowance for doubtful accounts based on expected credit losses (ECL’s) for trade receivables. The provision rates are based on days past due for its various customers. The provision matrix is initially based on the Group’s historical observed default rates as well as forward-looking information. At each reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed. The amount of ECLs is sensitive to changes in circumstances and forecast economic conditions. The Group’s historical credit loss experience and forecast of economic conditions may also not be representative of customers’ actual default in the future.

●

Determining the fair value of share-based payment transactions:

The fair value of share-based payment transactions is determined upon initial recognition by the Binomial model. The Binomial model is based on share price and exercise price and assumptions regarding expected volatility, term of share option, dividend yield and risk-free interest rate.

Equity

9 Months Ended

Sep. 30, 2020

EQUITY:

Equity

NOTE 3: EQUITY

a.	Composition of share capital:

September 30, 2020

December 31, 2019

Authorized

Issued and

outstanding

Authorized

Issued and

outstanding

Number of shares

Ordinary shares of NIS 0.04 par value each

25,000,000

22,482,630

25,000,000

22,236,368

b.	Movement in share capital:

Issued and outstanding capital:

	Number of shares		NIS par value
Balance at January 1, 2020		22,236,368		233,167
Issuance of shares – exercise of options		246,262		9,850

Balance at September 30, 2020		22,482,630		243,017

Balance at December 31, 2019		22,236,368		233,167

Share-Based Payments

9 Months Ended

Sep. 30, 2020

Share-based Payments

Share-Based Payments

NOTE 4: SHARE-BASED PAYMENTS

a.	Movement in share-based payment transactions during the nine-month period ended September 30, 2019 and 2020

	Number of options			*Weighted average exercise price()**
					$
Outstanding at January 1, 2019		2,425,192		$	6.60
Expired		(59,765	)		7.45
Forfeited		(44,665	)		7.18

Outstanding at September 30, 2019		2,320,762		$	6.57

Exercisable at September 30, 2019		1,217,329			7.50

	Number of options			*Weighted average exercise price()**
					$
Outstanding at January 1, 2020		2,213,812		$	7.10
Granted		215, 008			5.52
Exercised		(246,262	)		5.80

Expired		(526,917	)		6.00
Forfeited		(72,666	)		6.77

Outstanding at September 30, 2020		1,582,975		$	7.47

Exercisable at September 30, 2020		783,442		$	8.04

(*)	The exercise price of all options denominated in NIS and was translated to USD in the table above using the exchange rate as of September 30, 2020.

The weighted average remaining contractual life for the options outstanding as of September 30, 2020 was approximately five years.

The range of exercise prices for options outstanding as of September 30, 2020 was NIS 17.32 to NIS 31.19.

In January 2020, the Company granted to the Company’s Chief Executive Officer (“CEO”) upon his employment, 240,000 restricted stock units (“RSUs”) of which 60,000 RSUs were granted through to January 26, 2021, and 180,000 RSUs have been committed to be provided in three future grants of 60,000 RSUs upon each anniversary of the employment start date of the CEO with the Company. The terms of the 180,000 committed CEO RSU’s were amended subsequent to balance sheet date - See Note 6(b).

Additional Information to the Statements of Comprehensive Loss Items

9 Months Ended

Sep. 30, 2020

Additional Information To Statements Of Comprehensive Loss Items

Additional Information to the Statements of Comprehensive Loss Items

NOTE 5: ADDITIONAL INFORMATION TO THE STATEMENTS OF COMPREHENSIVE LOSS ITEMS

a.	Additional information on revenues:

Revenues reported in the financial statements for each group of similar products and services:

	Nine months ended September 30
	2020		2019
Revenues from lease	$	10,241	$	9,721
Revenues from sale		4,750		7,089

	$	14,991	$	16,809

Geographic information:

Revenues reported in the financial statements derived from the Company’s country of domicile (Israel) and foreign countries based on the location of the customers, are as follows:

	Nine months ended September 30
	2020			%		2019		%
U.S.	$	13,300			89	$	14,938		89
Europe		1,512			10		892		5
Israel		(4	)		0		230		1
Other		183			1		749		5

	$	14,991			100	$	16,809		100

b.	Cost of revenues:

	Nine months ended September 30, 2020
	2020		2019
Cost of revenues—lease	$	2,444	$	2,218
Cost of revenues—sales		1,048		1,469

	$	3,492	$	3,687

Events after the Reporting Period

9 Months Ended

Sep. 30, 2020

Disclosure of non-adjusting events after reporting period [abstract]

Events after the Reporting Period

NOTE 6: EVENTS AFTER THE REPORTING PERIOD

a.	On January 26, 2021, the Board of Directors approved the repricing of approximately 1.474 million Ordinary Shares (“Ordinary Shares”) that had previously been granted to officers, independent Board members, employees and consultants of the Company the pursuant to the Brainsway 2014 Share Incentive Plan, and the Brainsway Amended and Restated 2019 Share Incentive Plan (the “2014 Plan” and the “2019 Plan”, respectively) to an exercise price of $4.675 ($9.35 per ADS), being a price equal to the closing price per Ordinary Share on January 25, 2021, provided, however, that with respect to directors’ options, the repricing of each option will ,be subject to shareholders approval at an exercise price equal to the higher of (a) $4.675 ($9.35 per ADS) (b) the closing price per Ordinary Share on the last trading date before the date of approval by the shareholders of this proposal.

b.	The equity compensation package that the Company granted to the Company’s Chief Executive Officer (“CEO”) upon his employment, comprised of 240,000 performance-based restricted stock units (“RSUs”) of which 60,000 RSUs were granted through to January 26, 2021, and 180,000 RSUs have been committed to be provided in three future grants of 60,000 RSUs upon each anniversary of the employment start date of the CEO with the Company. These future grants, as originally contemplated, would have been subject to satisfaction of certain individual and corporate performance-based criteria as defined in the CEO’s employment agreement.

The Board of Directors has approved, subject to shareholder approval, to grant 180,000 RSUs to the CEO as an amendment to the terms of employment of the CEO, in lieu of future grants of such RSUs per above.

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Disclosure of initial application of standards or interpretations [abstract]

Basis of Preparation of the Interim Consolidated Financial Statements

a.	Basis of preparation of the interim consolidated financial statements:

The interim consolidated financial statements have been prepared in accordance with IAS 34, “Interim Financial Reporting.”

Judgments

(i)	Judgments:

Classification of leases:

Evaluation of whether to classify a lease as a finance lease or an operating lease in accordance with the criteria stipulated in IFRS 16 requires significant judgment.

Estimates and Assumptions

(ii)	Estimates and assumptions:

●

Grants from the Israel Innovation Authority (“IIA”):

●

Provision for allowance for doubtful accounts on trade receivables:

●

Determining the fair value of share-based payment transactions:

Equity (Tables)

9 Months Ended

Sep. 30, 2020

EQUITY:

Schedule of Composition of Share Capital

September 30, 2020

December 31, 2019

Authorized

Issued and

outstanding

Authorized

Issued and

outstanding

Number of shares

Ordinary shares of NIS 0.04 par value each

25,000,000

22,482,630

25,000,000

22,236,368

Schedule of Issued and Outstanding Capital

Issued and outstanding capital:

	Number of shares		NIS par value
Balance at January 1, 2020		22,236,368		233,167
Issuance of shares – exercise of options		246,262		9,850

Balance at September 30, 2020		22,482,630		243,017

Balance at December 31, 2019		22,236,368		233,167

Share-Based Payments (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payments

Schedule of Movement in Share-Based Payment

a.	Movement in share-based payment transactions during the nine-month period ended September 30, 2019 and 2020

	Number of options			*Weighted average exercise price()**
					$
Outstanding at January 1, 2019		2,425,192		$	6.60
Expired		(59,765	)		7.45
Forfeited		(44,665	)		7.18

Outstanding at September 30, 2019		2,320,762		$	6.57

Exercisable at September 30, 2019		1,217,329			7.50

	Number of options			*Weighted average exercise price()**
					$
Outstanding at January 1, 2020		2,213,812		$	7.10
Granted		215, 008			5.52
Exercised		(246,262	)		5.80

Expired		(526,917	)		6.00
Forfeited		(72,666	)		6.77

Outstanding at September 30, 2020		1,582,975		$	7.47

Exercisable at September 30, 2020		783,442		$	8.04

(*)	The exercise price of all options denominated in NIS and was translated to USD in the table above using the exchange rate as of September 30, 2020.

Additional Information to the Statements of Comprehensive Loss Items (Tables)

9 Months Ended

Sep. 30, 2020

Additional Information To Statements Of Comprehensive Loss Items

Schedule of Additional Information on Revenues

Revenues reported in the financial statements for each group of similar products and services:

	Nine months ended September 30
	2020		2019
Revenues from lease	$	10,241	$	9,721
Revenues from sale		4,750		7,089

	$	14,991	$	16,809

Schedule of Geographic Information

Revenues reported in the financial statements derived from the Company’s country of domicile (Israel) and foreign countries based on the location of the customers, are as follows:

	Nine months ended September 30
	2020			%		2019		%
U.S.	$	13,300			89	$	14,938		89
Europe		1,512			10		892		5
Israel		(4	)		0		230		1
Other		183			1		749		5

	$	14,991			100	$	16,809		100

Schedule of Cost of Revenues

	Nine months ended September 30, 2020
	2020		2019
Cost of revenues—lease	$	2,444	$	2,218
Cost of revenues—sales		1,048		1,469

	$	3,492	$	3,687

General (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
General (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 30, 2019
General
Negative cash flows from operating activities	$ 3,076	$ 6,014
Operating loss	$ 4,422	$ 6,485

Equity - Schedule of Composition of Share Capital (Details) - shares	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
EQUITY:
Ordinary shares of NIS 0.04 par value each, Authorized	25,000,000	25,000,000
Ordinary shares of NIS 0.04 par value each, Issued and outstanding	22,482,630	22,236,368	16,640,446

Equity - Schedule of Composition of Share Capital (Details) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
EQUITY:
NIS par value	$ 0.04	$ 0.04

Equity - Schdeule of Issued and Outstanding Capital (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
EQUITY:
Balance, shares	22,236,368	16,640,446
Balance	$ 233,167
Issuance of shares - exercise of options, shares	246,262
Issuance of shares - exercise of options	$ 9,850
Balance, shares	22,482,630	22,236,368
Balance	$ 243,017	$ 233,167

Share-Based Payment (Details Textual) - $ / shares		1 Months Ended	9 Months Ended
Share-Based Payment (Details Textual) - $ / shares	Jan. 26, 2021	Jan. 31, 2020	Sep. 30, 2020
IfrsStatementLineItems [Line Items]
Weighted average remaining contractual life			5 years
Non-adjusting events after reporting period [member] \| Chief Executive Officer [Member]
IfrsStatementLineItems [Line Items]
Performance-based restricted stock units	240,000	240,000
Restricted stock units granted	60,000
Restricted stock units future grants	180,000
Non-adjusting events after reporting period [member] \| Chief Executive Officer [Member] \| Future Grant One [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units future grants	60,000
Non-adjusting events after reporting period [member] \| Chief Executive Officer [Member] \| Future Grant Two [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units future grants	60,000
Non-adjusting events after reporting period [member] \| Chief Executive Officer [Member] \| Future Grant Three [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units future grants	60,000
Non-adjusting events after reporting period [member] \| Board of Directors [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units granted	180,000
Bottom of range [member]
IfrsStatementLineItems [Line Items]
Exercise Price			$ 17.32
Top of range [member]
IfrsStatementLineItems [Line Items]
Exercise Price			$ 31.19

Share-Based Payment - Schedule of Movement in Share-Based Payment (Details) - $ / shares

9 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Share-based Payments

Number of options, Outstanding

2,213,812

2,425,192

Number of options, Granted

215,008

Number of options, Exercised

(246,262)

Number of options, Expired

(526,917)

(59,765)

Number of options, Forfeited

(72,666)

(44,665)

Number of options, Outstanding

1,582,975

2,320,762

Number of options, Exercisable

783,442

1,217,329

Weighted average of exercise price, Outstanding

^[1]

$ 7.1

$ 6.6

Weighted average of exercise price, Granted

^[1]

5.52

Weighted average of exercise price, Exercised

^[1]

5.80

Weighted average of exercise price, Expired

^[1]

6.00

7.45

Weighted average of exercise price, Forfeited

^[1]

6.77

7.18

Weighted average of exercise price, Outstanding

^[1]

7.47

6.57

Weighted average of exercise price, Exercisable

^[1]

$ 8.04

$ 7.50

[1]	The exercise price of all options denominated in NIS and was translated to USD in the table above using the exchange rate as of September 30, 2020.

Additional Information to the Statements of Comprehensive Loss - Schedule of Additional Information on Revenues (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Additional Information To Statements Of Comprehensive Loss Items
Revenues from lease	$ 10,241	$ 9,721
Revenues from sale	4,750	7,089
Revenues	$ 14,991	$ 16,809

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_32&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_103&doctype=Standard
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_102&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2020-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2020-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Additional Information to the Statements of Comprehensive Loss Items - Schedule of Geographic Information (Details)) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
IfrsStatementLineItems [Line Items]
Revenues	$ 14,991	$ 16,809
Percentage of revenues	100.00%	100.00%
U.S. [Member]
IfrsStatementLineItems [Line Items]
Revenues	$ 13,300	$ 14,938
Percentage of revenues	89.00%	89.00%
Europe [Member]
IfrsStatementLineItems [Line Items]
Revenues	$ 1,512	$ 892
Percentage of revenues	10.00%	5.00%
Israel [Member]
IfrsStatementLineItems [Line Items]
Revenues	$ (4)	$ 230
Percentage of revenues	0.00%	1.00%
Other [Member]
IfrsStatementLineItems [Line Items]
Revenues	$ 183	$ 749
Percentage of revenues	1.00%	5.00%

- Definition

+ References

+ Details

Additional Information to the Statements of Comprehensive Loss - Schedule of Cost of Revenues (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
IfrsStatementLineItems [Line Items]
Cost of revenues	$ 3,492	$ 3,687
Cost of Revenue - Lease [Member]
IfrsStatementLineItems [Line Items]
Cost of revenues	2,444	2,218
Cost of Revenue - Sales [Member]
IfrsStatementLineItems [Line Items]
Cost of revenues	$ 1,048	$ 1,746

Events after the Reporting Period (Details Narrative) - Non-adjusting events after reporting period [member] - $ / shares		1 Months Ended
	Jan. 26, 2021	Jan. 31, 2020	Jan. 25, 2021
Officers, Independent Board Members, Employees and Consultants [Member] \| 2014 Plan and 2019 Plan [Member]
IfrsStatementLineItems [Line Items]
Ordinary shares granted	1,474,000
Exercise price of share	$ 4.675
Officers, Independent Board Members, Employees and Consultants [Member] \| 2014 Plan and 2019 Plan [Member] \| ADS [Member]
IfrsStatementLineItems [Line Items]
Exercise price of share	$ 9.35
Shareholders [Member]
IfrsStatementLineItems [Line Items]
Exercise price of share			$ 4.675
Shareholders [Member] \| ADS [Member]
IfrsStatementLineItems [Line Items]
Exercise price of share			$ 9.35
Chief Executive Officer [Member]
IfrsStatementLineItems [Line Items]
Performance-based restricted stock units	240,000	240,000
Restricted stock units granted	60,000
Restricted stock units future grants	180,000
Chief Executive Officer [Member] \| Future Grant One [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units future grants	60,000
Chief Executive Officer [Member] \| Future Grant Two [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units future grants	60,000
Chief Executive Officer [Member] \| Future Grant Three [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units future grants	60,000
Board of Directors [Member]
IfrsStatementLineItems [Line Items]
Restricted stock units granted	180,000